New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate ...

Can PSA derivatives reduce unnecessary prostate MRI after negative biopsy? Learn how simple markers may guide imaging ...

Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

In a randomized trial of men with a single suspicious lesion on MRI, targeted perilesional biopsy matched standard targeted and systematic biopsy for detecting clinically significant prostate cancer - ...

What these buzzy new tests can and can't tell you.

Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...

A combined PSMA-PET/MRI scanner better detected clinically significant prostate cancer in men on active surveillance. The addition of piflufolastat F18 (18 F-DCFPyL) prostate-specific membrane antigen ...

Seven years after the activation of the prostate biopsy service using Fusion technology, one of the most advanced innovations ...

Targeting men in the top 10% of genetic risk helped detect high-grade prostate cancer that conventional screening would miss, paving the way for more personalized and effective early detection ...

Anyone discouraged by the continued absence of a prostate cancer screening programme, the difficulties in getting a clear ...

Koelis, SAS ("Koelis" or the "Company", a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, recently announced that the Centers for Medicare & Medicaid ...